BridgeBio Pharma, Inc. annual free cash flow for fiscal 2025 was -$456 million, an increase of 14.0% from -$530 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | ($456M) | ($530M) | ($529M) | ($426M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Free Cash Flow | ($197M) | ($56M) | ($112M) | ($86M) | ($201M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BBIO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS
All BBIO financial statements → Interactive BBIO charts →
About TickerBase · Data methodology & sources